The GATHER1 and GATHER2 studies are highlighted. Ryan Haumschild, PharmD, MS, MBA: We know that avacincaptad pegol, or ACP, is one of the coming complement inhibitors that’s being evaluated for use in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results